Inactive Instrument

Lonza Group AG Stock Swiss Exchange

Equities

CH0013841017

Biotechnology & Medical Research

Real-time Estimate Cboe Europe 11:20:00 2024-05-03 am EDT
520.8 CHF 0.00% Intraday chart for Lonza Group AG
Sales 2024 * 6.65B 7.35B Sales 2025 * 7.5B 8.29B Capitalization 37.07B 40.94B
Net income 2024 * 904M 999M Net income 2025 * 1.11B 1.23B EV / Sales 2024 * 5.9 x
Net Debt 2024 * 2.18B 2.4B Net Debt 2025 * 2.47B 2.73B EV / Sales 2025 * 5.27 x
P/E ratio 2024 *
41.6 x
P/E ratio 2025 *
33.3 x
Employees -
Yield 2024 *
0.88%
Yield 2025 *
1.01%
Free-Float 95.87%
More Fundamentals * Assessed data

Latest transcript on Lonza Group AG

Managers TitleAgeSince
Chief Executive Officer 72 17-04-24
Director of Finance/CFO 52 21-11-30
Chief Operating Officer 55 22-07-31
Members of the board TitleAgeSince
Director/Board Member 63 14-04-15
Director/Board Member 66 14-04-15
Director/Board Member 58 22-05-04
More insiders
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (13.2%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%); - other (2.8%). Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).
Calendar
More about the company